(6 references)-
- 抗原
- PIR-A/B
- 抗原表位
- Extracellular Domain
- 适用
- 小鼠
- 宿主
- 大鼠
- 克隆类型
- 单克隆
- 应用范围
- Flow Cytometry (FACS), Immunoprecipitation (IP)
- 品牌
- BD Pharmingen™
- 产品特性
-
The 6C1 antibody reacts with common epitopes of PIR-A and PIR-B (Paired Immunoglobulin-liked Receptors) in all mouse strains tested (A/J, BALB/cJ, C3H, C57BL/6, DBA/1, DBA/2, NZB, and SJL). PIR-A and PIR-B are type-I transmembrane glycoproteins containing six Ig-like domains. There are multiple PIR-A proteins which are activating receptors by virtue of their intracellular association with the ITAM (Immunoreceptor Tyrosine-based Activation Motif)- containing Fc receptor γ chain (FcRγ) in mast cells and macrophages. FcRγ expression is required for PIR-A cell-surface expression on dendritic cells, B cells, and myeloid lineages. In contrast, PIR-B is an inhibitory receptor which contains various ITIMs (Immunoreceptor Tyrosine-based Inhibitory Motifs) in its cytoplasmic domain. These receptors are expressed on B cells, granulocytes, mast cells, dendritic cells, and monocytes/macrophages, but not on thymocytes, T lymphocytes, erythroid lineage cells, or NK cells. The level of cell-surface expression of these receptors increases as a function of B-cell activation and myeloid- and B-lineage differentiation. The 6C1 antibody immunoprecipitates molecules of 85- and 125- kDa, which correspond to PIRA and PIR-B, respectively. The expression of PIR-A/B on mouse spleen cells. BALB/c splenocytes were preincubated with Mouse BD Fc Block™ (Cat. no. 553141/553142) and stained with purified 6C1 monoclonal antibody (shaded histogram) followed by biotin-conjugated RG11/39.4 mAb (anti-rat IgG1, Cat. no. 553890, both histograms), then Streptavidin-PE (Cat. no. 554061, both histograms). Flow cytometry was performed on a BD FACScan™
BD Pharmingen™ Purified Rat Anti-Mouse PIR-A/B - Purified - Clone 6C1 - Isotype Rat IgG1, κ - Reactivity Ms - 0.1 mg - 纯化方法
- The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
- 免疫原
- Recombinant mouse PIR-A1 extracellular domain peptide and the mouse myeloid cell line, WEH13
- 克隆位点
- 6C1
- 亚型
- IgG1 kappa
-
- 应用备注
- Flow Cytometry System.
- 限制
- 仅限研究用
-
- 浓度
- 0.5 mg/mL
- 缓冲液
- Aqueous buffered solution containing ≤0.09 % sodium azide.
- 储存液
- Sodium azide
- 注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- 4 °C
- 储存方法
- Store undiluted at 4°C.
-
-
: "Paternal monoallelic expression of the paired immunoglobulin-like receptors PIR-A and PIR-B." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 96, Issue 12, pp. 6868-72, (1999) (PubMed).
: "Functional association of FcepsilonRIgamma with arginine(632) of paired immunoglobulin-like receptor (PIR)-A3 in murine macrophages." in: Blood, Vol. 94, Issue 5, pp. 1790-6, (1999) (PubMed).
: "Biochemical nature and cellular distribution of the paired immunoglobulin-like receptors, PIR-A and PIR-B." in: The Journal of experimental medicine, Vol. 189, Issue 2, pp. 309-18, (1999) (PubMed).
: "The paired Ig-like receptor PIR-B is an inhibitory receptor that recruits the protein-tyrosine phosphatase SHP-1." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 95, Issue 5, pp. 2446-51, (1998) (PubMed).
: "Paired immunoglobulin-like receptor (PIR)-A is involved in activating mast cells through its association with Fc receptor gamma chain." in: The Journal of experimental medicine, Vol. 188, Issue 5, pp. 991-5, (1998) (PubMed).
: "A novel pair of immunoglobulin-like receptors expressed by B cells and myeloid cells." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 94, Issue 10, pp. 5261-6, (1997) (PubMed).
-
: "Paternal monoallelic expression of the paired immunoglobulin-like receptors PIR-A and PIR-B." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 96, Issue 12, pp. 6868-72, (1999) (PubMed).
-
- 抗原
- PIR-A/B
-
You are here:
